Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma (Q81834393)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

0 references

1 reference

Keith M Skubitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Philip A Haddad

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

1 July 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

361-366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

Characterization of sarcomas by means of gene expression

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Differential gene expression in leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Classification and subtype prediction of adult soft tissue sarcoma by functional genomics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Molecular characterisation of soft tissue tumours: a gene expression study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Angiosarcoma of the face and scalp, prognosis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Radiation-induced angiosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Management of angiosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

A phase I study of ambulatory continuous infusion paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Phase II trial of paclitaxel in patients with soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Lack of vesicant injury following extravasation of liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Postirradiation angiosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Lymphangiosarcoma arising in chronic lymphedematous extremities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Cutaneous vascular proliferations. Part III. Malignant neoplasms, other cutaneous neoplasms with significant vascular component, and disorders erroneously considered as vascular neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Treatment of classical Kaposi's sarcoma with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Phase II trial of gemcitabine in advanced sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21140

7 January 2021

Identifiers

DOI

10.1002/CNCR.21140

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15948172%20AND%20SRC:MED&resulttype=core&format=json